Trial Profile

Clinical study of HDP-102 for the treatment of non-Hodgkin lymphoma

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 29 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs HDP 102 (Primary)
Indications Non-Hodgkin's lymphoma
Focus Adverse reactions

Most Recent Events

29 Apr 2025 New trial record
24 Apr 2025 According to Heidelberg Pharma AG media release, Clinical development of the second ADC program HDP-102 in patients with non-Hodgkin lymphoma (NHL) has started,received all the necessary approvals to start the clinical trial and expects the dosing of the first patient shortly.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com